The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Inclusion Criteria:

• Are SCLE, DLE and/or SLE that have completed the 24 week Treatment of the WillowStudy

• Have a Body Mass Index (BMI) within the less than or equal to (<=) 40 kilograms permeter square (inclusive) at Screening

• Participants who had successfully completed Week 48 of the Part 1 will have theopportunity to participate in the LTE Part 2. In exceptional cases and after Sponsorreview, participants who have completed the Week 48 visit of the Part 1 within theprevious 4-weeks may be considered for Part 2 participation based on eligibilityreview. Previous 4-weeks will be calculated from the Week 48 visit of Part 1

• Other protocol defined inclusion criteria could apply

Exclusion Criteria:

• Participants who experienced serious event(s) related to the study interventionduring the WILLOW study

• Other severe acute or chronic medical or psychiatric condition or laboratoryabnormality that may increase the risk associated with Long Term Extension (LTE)study participation

• Ongoing or active clinically significant viral (including Severe acute respiratorysyndrome coronavirus 2 [(SARS-CoV-2)], bacterial or fungal infection, or any majorepisode of infection requiring hospitalization

• Received LTE prohibited medication during the WILLOW study or after the WILLOW studyWeek 24

• Participation in any other investigational drug study after the WILLOW study Week 24

• Other protocol defined exclusion criteria could apply